Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT04322604Phase 3Completed
- Sponsor
- Allakos Inc.
- Start
- Jun 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lirentelimab in eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), sponsored by Allakos Inc.. Started Jun 2020; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic gastritis (EG)eosinophilic duodenitis (EoD)
Beyond the preview
Go deeper on NCT04322604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322604.